Cidara Therapeutics

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 % YTD return ytdreturn.com. Zacks similarly reported a 217.8 % YTD rally by late September nasdaq.com, reflecting further gains in October. The stock traded between US$10.14 and US$106.63 over the past year stockanalysis.com and surged 695.5 % year‑on‑year nasdaq.com. The rally was driven by positive trial data, accelerated regulatory milestones and speculative interest. Cidara’s Cloudbreak platform generated excitement because the CD388 candidate could

4 October 2025

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

Cidara Trading on Oct 3, 2025 On Friday morning Oct 3, CDTX was trading around $104 per share, up roughly 5.7% from Thursday’s close finviz.com. Trading volumes are high as investors digest the Oct 2 BARDA award news. (Finviz shows a sharp jump on Oct 2: GlobeNewswire’s BARDA release coincides with a ~5.7% stock bump finviz.com.) Cidara’s one-year chart is steeply upward – from around $10 a year ago to over $100 now (a nearly 900% one-year increase finviz.com). Most of that gain occurred since June, after positive Phase 2b results for CD388 and the $402M financing. CEO Jeffrey Stein noted on the Phase 3 dosing press release

3 October 2025

Biotechnology · İlaç Sektörü · NASDAQ:CDTX · Sağlık · Stock Market · Stocks · Yatırım

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock and Company Update as of September 24, 2025 Stock Performance & Technical Analysis Cidara’s stock has been on a tear in 2025, delivering triple-digit percentage gains. Year-to-date, CDTX has risen about +173% as of late September investing.com, driven by upbeat trial results and investor enthusiasm for its flu program. The stock recently surged over 20% in one day after the Phase 3 acceleration news, reaching an intraday high of approximately $87.75 on Sept. 24 marketbeat.com marketbeat.com. This is effectively a new 52-week (and all-time) high, far above its 52-week low of ~$10 marketbeat.com. By comparison, Cidara’s market capitalization now stands around $2.0–2.3 billion at these prices

24 September 2025

Biotech · Drug Development · Investor Updates · NASDAQ:CDTX · Pharma News · Stock Market